Robert Patrick Clarke

US Patent:

6788157, Sep 7, 2004

Filed:

Oct 28, 2002

Appl. No.:

10/281605

Inventors:

Robert M. Clarke - Gloucester MA

Assignee:

Analog Devices, Inc. - Norwood MA

International Classification:

H03B 1900

US Classification:

331 74, 455255, 455260

Abstract:

A programmable frequency synthesizer including a voltage-controlled oscillator, a regenerative frequency divider and a programmable integer divider, that provides wideband frequency coverage from a single narrowband oscillator. The voltage-controlled oscillator may generate a first signal having a first frequency. The regenerative frequency divider is coupled to the voltage-controlled oscillator and receives the first signal and performs a fractional multiplication of the first frequency of the first signal to provide a second signal a having a second frequency. The programmable integer divider is coupled to the regenerative frequency divider, and receives the second signal and divides the second frequency by a predetermined integer to provide a third signal having a third frequency.

US Patent:

7754242, Jul 13, 2010

Filed:

Mar 19, 2003

Appl. No.:

10/392333

Inventors:

Sujit K. Basu - Cambridge MA, US
Giovanni Caponetti - Piacenza, IT
Robert Clarke - Canton MA, US
Katharina J. Elbert - Cambridge MA, US

Assignee:

Alkermes, Inc. - Waltham MA

International Classification:

A61K 9/16
A61K 9/12

US Classification:

424489, 424 46, 424498, 424502

Abstract:

The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties.

US Patent:

8187637, May 29, 2012

Filed:

Mar 6, 2007

Appl. No.:

11/714999

Inventors:

David A. Edwards - Boston MA, US
Jonathan C. Man - Cambridge MA, US
Jeffrey P. Katstra - Watertown MA, US
Robert W. Clarke - Canton MA, US

Assignee:

Pulmatrix, Inc. - Lexington MA

International Classification:

A61K 9/00
A61K 9/08
A61K 9/10
A61K 9/12
A61K 9/14

US Classification:

424489, 424 46

Abstract:

Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.

US Patent:

8591866, Nov 26, 2013

Filed:

Apr 25, 2012

Appl. No.:

13/455585

Inventors:

David A. Edwards - Boston MA, US
Jonathan Chun-Wah Man - Cambridge MA, US
Jeffrey P. Katstra - Watertown MA, US
Robert W. Clarke - Medfield MA, US

Assignee:

Pulmatrix, Inc. - Lexington MA

International Classification:

A61K 9/00
A61K 9/12
A61K 9/14

US Classification:

424 46, 424489

Abstract:

Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.

US Patent:

8627821, Jan 14, 2014

Filed:

Jul 10, 2007

Appl. No.:

11/827031

Inventors:

David A. Edwards - Boston MA, US
Mark J. Gabrielson - Ridgefield CT, US
Robert William Clarke - Canton MA, US
Wesley H. Dehaan - Chelmsford MA, US
Matthew Frederick Brande - Bristol CT, US
Jonathan Chun-Wah Man - Bellevue WA, US

Assignee:

Pulmatrix, Inc. - Lexington MA

International Classification:

A62B 7/00
A61M 15/00
A61M 16/00
F16K 31/02
A62B 9/00
A61B 5/08

US Classification:

12820522, 12820527, 12820024, 12820222, 12820421, 12820422, 12820423, 12820523, 600529, 600530, 600531, 600532, 600533, 600534, 600535, 600536, 600537, 600538, 600539, 600540, 600541, 600542, 600543

Abstract:

Methods and devices to determine rate of particle production and the size range for the particles produced for an individual are described herein. The device () contains a mouthpiece (), a filter (), a low resistance one-way valve (), a particle counter () and a computer (). Optionally, the device also contains a gas flow meter (). The data obtained using the device can be used to determine if a formulation for reducing particle exhalation should be administered to an individual.

US Patent:

20050207983, Sep 22, 2005

Filed:

Nov 17, 2004

Appl. No.:

10/990996

Inventors:

David Edwards - Boston MA, US
Jonathan Man - Cambridge MA, US
Jeffrey Katstra - Watertown MA, US
Robert Clarke - Canton MA, US

International Classification:

A61L009/04
A61K048/00
A61K038/17
A61K031/70
A61K031/715

US Classification:

424044000, 514002000, 514044000, 514054000, 514561000

Abstract:

Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.

US Patent:

20070041912, Feb 22, 2007

Filed:

Sep 4, 2003

Appl. No.:

10/550471

Inventors:

Elliot Ehrich - Lincoln MA, US
Daniel Deaver - Franklin MA, US
Robert Clarke - Canton MA, US
Michael Lipp - Framingham MA, US

Assignee:

ADVANCED INHALATION RESEARCH, INC. - Cambridge MA

International Classification:

A61K 31/4747
A61L 9/04

US Classification:

424046000, 514278000

Abstract:

The invention relates to a method for treating a disease characterized by a constrictive airway comprising administering to a patient in need thereof via inhalation a pharmaceutical composition comprising trospium, wherein said patient achieves an effective therapy for at least 10 hours. The trospium composition is preferably a particulate formulation useful for administration via a dry powder inhaler. In a preferred embodiment, the composition further comprises a second active agent, such as a beta-2 agonist. A particularly preferred second active agent is formoterol, wherein the trospium, formoterol composition is manufactured by spray drying a mixture comprising trospium and formoterol.

US Patent:

20110123574, May 26, 2011

Filed:

Oct 19, 2010

Appl. No.:

12/907584

Inventors:

Sujit K. Basu - Cambridge MA, US
Giovanni Caponetti - Piacenza PC, IT
Robert Clarke - Canton MA, US
Katharina J. Elbert - Cambridge MA, US

Assignee:

Alkermes, Inc. - Waltham MA

International Classification:

A61K 9/00
A61K 31/137
A61K 31/46
A61P 11/08
A61P 11/00

US Classification:

424400, 514653, 514304

Abstract:

The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties.